Cytosorbents (CTSO) Other Non Operating Income (2015 - 2026)

Cytosorbents has reported Other Non Operating Income for 12 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 140.74% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 2262.33% YoY), and the FY2025 full-year result was $9.3 million, up 320.62% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$1.2 million, down from $193000.0 in the prior quarter.
• The five-year high for Other Non Operating Income was $6.2 million in Q2 2025, with the low at -$4.9 million in Q4 2024.
• Historically, Other Non Operating Income has averaged $198175.6 across 5 years, with a median of -$64000.0 in 2025.
• Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 1177.6% — and 2025, when it soared 1235.66%.
• Cytosorbents' Other Non Operating Income stood at $4.5 million in 2022, then slumped by 40.61% to $2.7 million in 2023, then slumped by 282.8% to -$4.9 million in 2024, then soared by 103.93% to $193000.0 in 2025, then tumbled by 736.27% to -$1.2 million in 2026.
• The last three Other Non Operating Income figures came in at -$1.2 million (Q1 2026), $193000.0 (Q4 2025), and -$64000.0 (Q3 2025), per Business Quant data.